Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes

Autor: János Nagy, László Bognár, Normann L. Block, Laura Vízkeleti, Aliz Juhász, Andrea Treszl, Almos Klekner, Géza Mezey, Margit Balázs, Gabor Halmos, Andrew V. Schally
Rok vydání: 2014
Předmět:
Adult
Male
Receptors
Neuropeptide
endocrine system
Cancer Research
medicine.medical_specialty
Growth-hormone-releasing hormone receptor
RNA Splicing
medicine.medical_treatment
Kaplan-Meier Estimate
Growth Hormone-Releasing Hormone
Ligands
Receptors
Pituitary Hormone-Regulating Hormone
Internal medicine
medicine
Frozen Sections
Humans
Tensin
PTEN
Epidermal growth factor receptor
Receptor
Aged
Regulation of gene expression
Hungary
biology
Brain Neoplasms
Reverse Transcriptase Polymerase Chain Reaction
Gene Expression Profiling
Growth factor
PTEN Phosphohydrolase
General Medicine
Middle Aged
Prognosis
Growth hormone–releasing hormone
ErbB Receptors
Gene Expression Regulation
Neoplastic
Endocrinology
Oncology
Cancer research
biology.protein
Female
Glioblastoma
hormones
hormone substitutes
and hormone antagonists
Zdroj: Journal of Cancer Research and Clinical Oncology. 140:1641-1649
ISSN: 1432-1335
0171-5216
DOI: 10.1007/s00432-014-1716-1
Popis: Glioblastoma (GB) is the most frequent brain tumor. Despite recent improvement in therapeutic strategies, the prognosis of GB remains poor. Growth hormone-releasing hormone (GHRH) may act as a growth factor; antagonists of GHRH have been successfully applied for experimental treatment of different types of tumors. The expression profile of GHRH receptor, its main splice variant SV1 and GHRH have not been investigated in human GB tissue samples. We examined the expression of GHRH, full-length pituitary-type GHRH receptor (pGHRHR), its functional splice variant SV1 and non-functional SV2 by RT-PCR in 23 human GB specimens. Epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog gene (PTEN) expression levels were also evaluated by quantitative RT-PCR. Correlations between clinico-pathological parameters and gene expressions were analyzed. Expression of GHRH was found to be positive in 61.9 % of samples. pGHRH receptor was not expressed in our sample set, while SV1 could be detected in 17.4 % and SV2 in 8.6 % of the GB tissues. In 65.2 and 78.3 % of samples, significant EGFR over-expression or PTEN under-representation could be detected, respectively. In 47.8 % of cases, EGFR up-regulation and PTEN down-regulation occurred together. Survival was significantly poorer in tumors lacking GHRH expression. This worse prognosis in GHRH negative group remained significant even if SV1 was also expressed. Our study shows that GHRH and SV1 genes expressed in human GB samples and their expression patterns are associated with poorer prognosis.
Databáze: OpenAIRE
Externí odkaz: